October 19, 2017
BioTissue Announces Strategic Agreement with Optima Pharmazeutische GmbH to Distribute its Natural Ocular Cleanser in Germany
Preservative-free Cliradex with 4-Terpineol now available to patients in Germany
MIAMI and MUNICH/Hallbergmoos, GERMANY, October 19, 2017 – BioTissue®, a business unit of TissueTech™, Inc., is pleased to announce a strategic agreement with Optima Pharmazeutische GmbH, a leading distributor of ophthalmic products for the treatment of dry eye, blepharitis and meibomian gland dysfunction (MGD) in Germany and Austria. The agreement supports efforts to bring BioTissue’s natural ocular cleanser formulated with 4-Terpineol, Cliradex®, to the German eye care professionals market. Cliradex is a Class I medical device as covered by the Medical Devices Directive (Directive 93/42/EEC).
“We are excited about this opportunity to work with Optima to bring our leading natural ocular cleanser to eye care professionals and patients in Germany,” said Thomas G. Daniells, Chief Commercial Officer, BioTissue. “With its strong track record of working with eye care professionals in Germany, Optima will support efforts to distribute Cliradex, a preservative-free cleanser for the eyelashes, eyelids and face.”
Cliradex towelettes are natural, preservative-free, lid, lash, and facial cleansers formulated with 4-Terpineol (T40). Unlike other remedies, Cliradex contains no harmful chemicals or fatty oils, and is safe to use as part of a daily ocular hygiene routine. Regular ocular cleansing is important for people with conditions such as Demodex, blepharitis, rosacea, dry eye, conjunctivitis and other eye disorders.”
Stefan Kroll, Managing Director of Optima Pharmazeutische GmbH said, “Optima is pleased to be working with BioTissue to bring this leading ocular cleanser and hygiene product to German and Austrian eye care professionals, for the treatment of moderate to severe eye irritations and disorders. We are excited about the potential in the market and the ability to help patients throughout Germany and Austria with this treatment and ocular hygiene product.”
BioTissue, a business unit of TissueTech, Inc., develops and markets regenerative therapies that allow eye care professionals to advance the standard of care for treating the ocular surface. Its core products include cryopreserved amniotic membrane and umbilical cord-based tissue with innate therapeutic actions scientifically proven to heal the ocular surface. The Company’s proprietary CryoTek® preservation method ensures the tissue retains its biologic activity and healing components. To date, more than 300,000 allografts have been transplanted collectively by BioTissue and sister company Amniox Medical (TissueTech business units).
About Optima Pharmazeutische GmbH
Optima Pharmazeutische GmbH develops, produces and distributes innovative medical products in the fields of ophthalmology, otorhinolaryngology and pneumology. In ophthalmology, our product portfolio is focused on the therapy of Dry Eye, blepharitis and MGD, first aid for accidents and chemical burns of the eyes. Ophthalmology has remained one of our core competencies, in particular dry eye disease for which we have developed a liposomal eye spray, which is unique in effect and application worldwide. Our products are available in more than 20 countries under different brand marks.